Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase 3 study of APL-130277 in Parkinson's disease with OFF episodes
2016-000637-43Phase 3Completed
- Sponsor
- Sunovion
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apomorphine in Parkinson's disease (PD), sponsored by Sunovion. Primary endpoint: Incidence of adverse events in the long-term safety phase. Started Mar 2016; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-000637-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000637-43.